0 BioPorto hopes to finish its clinical examination and present a De Novo application to the US FDA for pediatric utilization of its NGAL kidney test this late spring March 3, 2021 Jasyon Delgado The Danish group likewise mentioned it anticipates US take a look at outcomes for its